Skip to main content
. 2012 Mar 11;61(10):1735–1743. doi: 10.1007/s00262-011-1194-0

Fig. 4.

Fig. 4

CD40 agonist treatment inhibited ovarian tumour cell growth. The ovarian carcinoma cell lines and breast carcinoma cell line (MCF-7) were treated for 48 h with 1 μg/ml recombinant soluble human CD40 ligand (rshCD40L) or 1 μg/ml anti-CD40 agonist antibody, and cell growth was assessed by MTT assay. Data are expressed as per cent growth inhibition. Data are from three independent experiments (mean + standard deviation). *P < 0.05 versus MCF-7